THE HAGUE, Netherlands,
June 24, 2019 /PRNewswire/ -- At
Metabolomics 2019 (metabolomics2019.org), Bruker highlights
innovative mass spectrometry (MS) and Nuclear Magnetic Resonance
(NMR) systems and novel high-value solutions for molecular
phenomics and clinical metabolomics research.
The proven Bruker IVDr NMR solution, which is based on a
fully automated and standardized 600 MHz NMR platform, is uniquely
suitable for large-scale, quantitative metabolomics and
translational phenomics studies. Its standardized and automated
Bruker IVDr (B.I.) Methods 2.0 are now available on the
AVANCE® III HD, as well as on the newest
AVANCE® NEO NMR console platform. The B.I. 2.0 methods
have been further expanded with a new plasma and serum
quantification package B.I.Quant-PS 2.0., which detects and
quantifies up to 40 different metabolites using 1D NOESY NMR.
B.I.Quant-PS 2.0 offers enhanced interactive reporting
functions with additional quantification quality assessment.
The new B.I. Inborn Errors of Metabolism (IEM) panel is
for research use only (RUO). It has been developed in collaboration
with the Metagene consortium (www.metagene.de), and it
generates NMR metabolic findings on inborn errors of metabolism in
newborns, children and late onset adults. These can be compared to
Metagene's database of almost 1,000 diseases and
differential diagnoses for translational research in
pediatrics.
Dr. med. Friedrich Trefz,
co-founder of Metagene and professor at the University
Children's Hospital Heidelberg in Germany, commented: "For the first time an
automatic interpretation of the quantification results is possible
by using Metagene's extensive database to support
translational research. This is truly novel and of high value
in the IEM field, as NMR can detect and quantify large numbers of
chemically different IEM markers simultaneously, something that
otherwise would require multiple conventional analytical
methods."
Bruker also announces new MS solutions for next-generation
metabolomics and translational phenomics research. Ultra-high
sensitivity 4D lipidomics methods on the timsTOF Pro system
allows for deep lipidome profiling in just 30 minutes using the
PASEF method. In addition to quantifying more than 500 lipids with
high accuracy and reproducibility from just 1ul of human plasma,
accurate collision cross-sections (CCS) can be obtained to create
4D libraries to facilitate identification.
This approach can be combined with spatial molecular
distributions in tissues obtained from MALDI imaging on the new
timsTOF fleX system in a label-free
SpatialOMxTM workflow. The new timsTOF
fleX bridges the divide between molecular tissue imaging
and body fluids analyses by combining high-spatial resolution MALDI
imaging with deep 4D LC-TIMS-MS/MS multi-omics analyses on a single
platform. A new automated software workflow combines the annotation
of lipids and metabolites in molecular tissue images, using
SCiLS Lab 2020 and MetaboScape 5.0 software. This
makes the robust, ultra-high sensitivity timsTOF
fleX an invaluable research tool to study
heterogeneity in tissue lipidomics and metabolomics.
A new deep discovery metabolomics workflow,
FIA-CASI-MRMS, allows for the determination of Isotopic Fine
Structure (IFS) on large numbers of unknown metabolites. Powered by
Bruker's revolutionary scimaX MRMS magnetic resonance mass
spectrometer and MetaboScape 5.0 software, the continuous
accumulation of selected ions (CASI) offers enhanced dynamic range
that greatly increases peak density and sensitivity. Flow injection
analysis (FIA) yields a combined mass spectrum with IFS unambiguous
molecular formulae for thousands of unknown metabolites. The
FIA-CASI-MRMS discovery workflow gives an unprecedented
level of confidence when annotating unknown metabolites, providing
deeper access into the 'dark metabolome'.
Combining the annotation capabilities of MRMS with NMR is the
basis of a de novo strategy for the structural elucidation
of urinary metabolites. Dr. Matthew
Lewis and the group at the UK National Phenome Centre at
Imperial College London have detailed this novel molecular
profiling workflow in the journal Analytical Chemistry
(doi.org/10.1021/acs.analchem.9b00241). MRMS provides a
high-confidence starting point for NMR analysis, increases the
efficiency and reduces the time required for complete structural
elucidation. The work also details a novel, urine-based pipeline
solution that facilitates metabolite extraction, concentration and
purification. This creates a reusable "fraction bank" for long-term
storage that can be re-visited for further analysis later.
A similar molecular profiling workflow is now being used at the
Australian National Phenome Center (ANPC), in collaboration with
Bruker and Murdoch University in Perth, Western
Australia. For its large-scale metabolic phenotyping
studies, the ANPC has standardized NMR on Bruker's IVDr
platform and on the impact II QTOF 'phenomics
workhorse' for the characterization of complex mixtures of
polar and non-polar urinary metabolites within the Australian
population. The Western Australian Health Translation Network aims
to develop the world's premier phenomics center for the advancement
of precision medicine with multiple Bruker IVDr NMR and
impact II systems to support the required increase in
throughput.
To learn more, please join our lunch symposium at
Metabolomics 2019 on Thursday, June
27th, 2019. Guest speakers Dr. Catherine
Vasilopoulou (Max Planck Institute Martinsried, Germany), and Prof. Gary Frost (Imperial College London, UK) will present their recent
research.
About Bruker Corporation (Nasdaq: BRKR)
Bruker is enabling scientists to make breakthrough discoveries
and develop new applications that improve the quality of human
life. Bruker's high-performance scientific instruments and
high-value analytical and diagnostic solutions enable scientists to
explore life and materials at molecular, cellular and microscopic
levels. In close cooperation with our customers, Bruker is enabling
innovation, improved productivity and customer success in life
science molecular research, in applied and pharma applications, in
microscopy and nanoanalysis, and in industrial applications, as
well as in cell biology, preclinical imaging, clinical phenomics
and proteomics research and clinical microbiology. For more
information, please visit: www.bruker.com.
Investor Contact:
Pamela
Clark
Investor Relations
Bruker Corporation
T: +1 (978) 663-3660, ext. 1479
E: Investor.Relations@bruker.com
Media
Contact:
Dr. Thorsten
Thiel
VP of Group Marketing
Bruker BioSpin
Group
T: +49 (721)
5161–6500
E: thorsten.thiel@bruker.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/bruker-announces-new-phenomics-research-tools-at-metabolomics-2019-300873250.html
SOURCE Bruker Corporation